Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-038595
Filing Date
2023-11-13
Accepted
2023-11-13 16:04:10
Documents
52
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ryzb-20230930.htm   iXBRL 10-Q 1827555
2 EX-31.1 exhibit311.htm EX-31.1 8282
3 EX-31.2 exhibit312.htm EX-31.2 8007
4 EX-32.1 exhibit321.htm EX-32.1 5055
  Complete submission text file 0001628280-23-038595.txt   6917533

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ryzb-20230930.xsd EX-101.SCH 39227
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ryzb-20230930_cal.xml EX-101.CAL 51419
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ryzb-20230930_def.xml EX-101.DEF 165701
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ryzb-20230930_lab.xml EX-101.LAB 537153
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ryzb-20230930_pre.xml EX-101.PRE 334128
46 EXTRACTED XBRL INSTANCE DOCUMENT ryzb-20230930_htm.xml XML 953055
Mailing Address 5505 MOREHOUSE DRIVE, SUITE 300 SAN DIEGO CA 92121
Business Address 5505 MOREHOUSE DRIVE, SUITE 300 SAN DIEGO CA 92121 (619) 937-2754
RayzeBio, Inc. (Filer) CIK: 0001825367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41799 | Film No.: 231398520
SIC: 2834 Pharmaceutical Preparations